Table 1 |
||||
|
Baseline characteristics of the AS study population |
||||
|
Total |
IFX |
ETA |
ADA |
|
|
|
||||
|
Number of patients |
220 |
32 |
137 |
51 |
|
Age (yrs) |
42.9 ± 11.9 |
45.8 ± 10.1 |
41.9 ± 11.6 |
43.7 ± 13.3 |
|
Gender (male) (n, %) |
152 (69) |
20 (63) |
96 (70) |
36 (71) |
|
Duration of symptoms (yrs) |
15 (1 to 53) |
21 (2 to 49) |
15 (1 to 47) |
11 (1 to 53) |
|
Time since diagnosis (yrs) |
7 (0 to 45) |
16 (0 to 35)* |
7 (0 to 44) |
6 (0 to 45) |
|
HLA-B27+ (n, %) |
174 (81) |
24 (75) |
108 (82) |
42 (82) |
|
History of IBD (n, %) |
20 (9) |
8 (26)† |
7 (5) |
4 (8) |
|
History of uveitis (n, %) |
64 (29) |
13 (40) |
44 (32) |
7 (14)‡ |
|
History of psoriasis (n, %) |
13 (6) |
3 (9) |
8 (6) |
13 (6) |
|
Peripheral arthritis (n, %) |
37 (17) |
5 (16) |
27 (20) |
5 (10) |
|
Current NSAID use (n, %) |
158 (72) |
24 (75) |
102 (75) |
32 (63) |
|
Current DMARD use (n, %) |
45 (21) |
10 (31) |
28 (20) |
7 (14) |
|
BASDAI (range 0 to 10) |
6.1 ± 1.7 |
6.1 ± 1.4 |
6.2 ± 1.7 |
5.9 ± 1.7 |
|
ASDAS |
3.8 ± 0.8 |
3.8 ± 0.6 |
3.8 ± 0.8 |
3.7 ± 0.9 |
|
Physician's GDA (range 0-10) |
5 (0 to 9) |
5 (0 to 8) |
5 (0 to 9) |
3 (0 to 9)‡ |
|
Patient's GDA (range 0 to 10) |
7 (1 to 10) |
6 (1 to 9) |
7 (1 to 10) |
6 (1 to 10) |
|
ESR (mm/h) |
21 (2 to 101) |
24 (2 to 90) |
20 (2 to 101) |
23 (2 to 74) |
|
CRP (mg/l) |
13 (2 to 99) |
15 (2 to 74) |
12 (2 to 99) |
14 (2 to 92) |
|
BASFI (range 0 to 10) |
6.1 (0.3 to 9.7) |
6.3 (1.9 to 9.6) |
5.9 (0.3 to 9.7) |
6.3 (0.4 to 9.5) |
|
Chest expansion (cm) |
3.0 (0.5 to 43.0) |
2.5 (0.5 to 7.0) |
3.0 (0.5 to 22.0) |
3.5 (0.0 to 43.0)§ |
|
Modified Schober test (cm) |
2.9 (0.0 to 7.0) |
2.4 (0.5 to 6.0) |
2.8 (0.1 to 7.0) |
3.2 (0.0 to 5.5) |
|
Occiput to wall distance (cm) |
4.9 (0.0 to 34.5) |
9.0 (0.0 to 26.0)^ |
4.5 (0.0 to 34.5) |
3.5 (0.0 to 30.0) |
|
Lateral lumbar flexion L (cm) |
8.0 (0.0 to 30.0) |
7.0 (2.0 to 15.0) |
9.0 (0.0 to 30.0) |
8.0 (1.0 to 20.5) |
|
Lateral lumbar flexion R (cm) |
8.0 (0.0 to 29.0) |
8.0 (0.5 to 17.0) |
8.0 (0.0 to 29.0) |
7.5 (1.0 to 20.0) |
|
|
||||
|
Values are mean ± SD or median (range) unless otherwise indicated. AS, Ankylosing Spondylitis; IFX, infliximab; ETA, etanercept; ADA, adalimumab; HLA-B27+, human leukocyte antigen B27 positive; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; DMARD, disease-modifying antirheumatic drug; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; GDA, global disease activity; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASFI, Bath Ankylosing Spondylitis Functional Index; L, left; R, right. * P < 0.05 compared to ETA group and P = 0.052 compared to ADA group. † P < 0.05 compared to ETA group and P = 0.050 compared to ADA group. ‡ P < 0.05 compared to IFX and ETA groups. § P < 0.05 compared to ETA group. ^ P < 0.05 compared to ETA and ADA groups. |
||||
|
Arends et al. Arthritis Research & Therapy 2011 13:R94 doi:10.1186/ar3369 |
||||
